Christian Henker1, Thomas Kriesen1, Moritz Scherer2, Änne Glass3, Andreas von Deimling4, Martin Bendszus5, Marc-André Weber6, Christel Herold-Mende2, Andreas Unterberg2, Jürgen Piek1. 1. Department of Neurosurgery, University Medicine of Rostock, Rostock, Germany. 2. Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany. 3. Institute for Biostatistics and Informatics in Medicine, University Medicine of Rostock, Rostock, Germany. 4. Department of Neuropathology, Institute of Pathology, University Hospital, and, CCU Neuropathology German Cancer Research Center (DKFZ), and DKTK, Heidelberg, Germany. 5. Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany. 6. Institute of Diagnostic and Interventional Radiology, University Medicine of Rostock, Rostock, Germany.
Abstract
BACKGROUND: Seizures are a common initial symptom of malignant brain tumors such as glioblastoma (GBM). However, why some of these tumors are epileptogenic and others never trigger seizures remains controversial. OBJECTIVE: To identify potential clinical and radiological features of epileptogenic tumors and the effect of initial seizures on survival. METHODS: The analyzed patient cohort was retrospectively compiled (bicentric), only isocitrate dehydrogenase wild-type GBMs were included. Volumetric assessment was performed on pretreatment magnetic resonance imaging with the aid of a semi-automated 3D measurement (tumor, necrosis, and edema volume). Two ratios were calculated, reflecting the proportion of peritumoral edema and necrosis (NTR) toward the tumor volume. For overall survival analyses, only patients after a surgical resection (residual tumor volume <2 cm3) followed by standard radiation and chemotherapy were included. RESULTS: Pretreatment seizures occurred in 33% of cases (n = 224), younger patients (≤60 yr) were predominantly affected (P = .022). All measured volumes were inversely correlated with the onset of seizures (P = .001). In multivariate analyses, the total tumor volume and the NTR were considerably smaller within epileptogenic GBMs (P = .050, P = .019, respectively). A positive statin intake was associated with significantly lesser seizure (P = .007, odds ratio 4.94). Neither the occurrence of seizures nor the intake of statins had an impact on OS (P = .357, P = .507, respectively). CONCLUSION: The size and amount of necrosis was significantly smaller in epileptogenic GBMs, maybe owed to the fact that these tumors were clinically detected at an earlier stage of their growth. Furthermore, the intake of statins was associated with a decreased occurrence of pretreatment seizures.
BACKGROUND:Seizures are a common initial symptom of malignant brain tumors such as glioblastoma (GBM). However, why some of these tumors are epileptogenic and others never trigger seizures remains controversial. OBJECTIVE: To identify potential clinical and radiological features of epileptogenic tumors and the effect of initial seizures on survival. METHODS: The analyzed patient cohort was retrospectively compiled (bicentric), only isocitrate dehydrogenase wild-type GBMs were included. Volumetric assessment was performed on pretreatment magnetic resonance imaging with the aid of a semi-automated 3D measurement (tumor, necrosis, and edema volume). Two ratios were calculated, reflecting the proportion of peritumoral edema and necrosis (NTR) toward the tumor volume. For overall survival analyses, only patients after a surgical resection (residual tumor volume <2 cm3) followed by standard radiation and chemotherapy were included. RESULTS: Pretreatment seizures occurred in 33% of cases (n = 224), younger patients (≤60 yr) were predominantly affected (P = .022). All measured volumes were inversely correlated with the onset of seizures (P = .001). In multivariate analyses, the total tumor volume and the NTR were considerably smaller within epileptogenic GBMs (P = .050, P = .019, respectively). A positive statin intake was associated with significantly lesser seizure (P = .007, odds ratio 4.94). Neither the occurrence of seizures nor the intake of statins had an impact on OS (P = .357, P = .507, respectively). CONCLUSION: The size and amount of necrosis was significantly smaller in epileptogenic GBMs, maybe owed to the fact that these tumors were clinically detected at an earlier stage of their growth. Furthermore, the intake of statins was associated with a decreased occurrence of pretreatment seizures.
Authors: Luis F Rendon; Ishaan A Tewarie; David J Cote; Aaron Gabriel; Timothy R Smith; Marike L D Broekman; Rania A Mekary Journal: Drugs Date: 2022-02-05 Impact factor: 9.546
Authors: Johannes Kasper; Nicole Hilbert; Tim Wende; Michael Karl Fehrenbach; Florian Wilhelmy; Katja Jähne; Clara Frydrychowicz; Gordian Hamerla; Jürgen Meixensberger; Felix Arlt Journal: Curr Oncol Date: 2021-04-07 Impact factor: 3.677
Authors: Yahya Ahmadipour; Laurèl Rauschenbach; Alejandro Santos; Marvin Darkwah Oppong; Lazaros Lazaridis; Carlos M Quesada; Andreas Junker; Daniela Pierscianek; Philipp Dammann; Karsten H Wrede; Björn Scheffler; Martin Glas; Martin Stuschke; Ulrich Sure; Ramazan Jabbarli Journal: Neurooncol Adv Date: 2020-11-18
Authors: Matthew T Carr; Camille J Hochheimer; Andrew K Rock; Alper Dincer; Lakshmi Ravindra; Fan Lily Zhang; Charles F Opalak; Nora Poulos; Adam P Sima; William C Broaddus Journal: Sci Rep Date: 2019-12-27 Impact factor: 4.379